Nanodelivery strategies in cancer chemotherapy: Biological rationale and pharmaceutical perspectives

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1577-1590

  Mattheolabakis, George ^a   Rigas, Basil ^a   Constantinides, Panayiotis P ^b,c  

^a STONY BROOK UNIVERSITY   (United States)

^b Biopharmaceutical and Drug Delivery Consulting   (United States)

^c Medicon Pharmaceuticals Inc   (United States)

Author keywords

cancer chemotherapy; multifunctional nanoparticles; nanodelivery; pharmaceutical perspectives; targeted nanocarriers; tumor biology

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CARBON NANOTUBE; CELL PENETRATING PEPTIDE; CYTARABINE; DAUNORUBICIN; DENDRIMER; DOXORUBICIN; DRUG VEHICLE; EMPAC; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; MAGNETIC NANOPARTICLE; MDC 917; MULTI WALLED NANOTUBE; NANOCARRIER; NANOCONJUGATE; NANOPARTICLE; PACLITAXEL; PACLITAXEL TOCOSOL; PHOSPHATIDYLETHANOLAMINE; PHOSPHOIBUPROFEN; POLYMER; POLYMERSOME; SINGLE WALLED NANOTUBE; SOLID LIPID NANOPARTICLE; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; COLLOID; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; INTERNALIZATION; LIPID BILAYER; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MICELLE; MOLECULARLY TARGETED THERAPY; NANOEMULSION; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PH; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; NANOSTRUCTURES; TISSUE DISTRIBUTION;

EID: 84869427376     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.128     Document Type: Review

References (130)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
2. Folkman J, Greenspan HP. Influence of geometry on control of cell growth. Biochim. Biophys. Acta 417(3-4), 211-236 (1975).
3. Stenzinger W, Bruggen J, Macher E, Sorg C. Tumor angiogenic activity (TAA) production in vitro and growth in the nude mouse by human malignant melanoma. Eur. J. Cancer Clin. Oncol. 19(5), 649-656 (1983).
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986).
5. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59(6), 491-504 (2007).
6. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
7. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136-151 (2011).
8. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440-4445 (2000).
9. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors. Jpn. J. Clin. Oncol. 39(11), 756-766 (2009).
10. Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67(5), 975-980 (1993).
11. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56(6), 1194-1198 (1996).
12. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49(16), 4373-4384 (1989).
13. Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumours: Studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 77(11), 1726-1731 (1998).
14. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8(4), 1284-1291 (2002).
15. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3(2), 177-182 (1997).
16. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev. 63(8), 623-629 (2010).
17. Tang R, Ji W, Wang C Amphiphilic block copolymers bearing ortho ester side-chains: pH-dependent hydrolysis and self-assembly in water. 10(2), 192-201 (2010).
18. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control Release 82(1), 17-27 (2002).
19. Masson C, Garinot M, Mignet N et al. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J. Control Release 99(3), 423-434 (2004).
20. Kale AA, Torchilin VP. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug. Chem. 18(2), 363-370 (2007).
21. Sawant RM, Hurley JP, Salmaso S et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17(4), 943-949 (2006).
22. Gregoriadis G. Liposome technology (3rd Edition). Informa Healthcare, New York, NY, USA (2007).
23. Aluri S, Janib SM, Mackay JA. Environmentally responsive peptides as anticancer drug carriers. Adv. Drug Deliv. Rev. 61(11), 940-952 (2009).
24. Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 9(3), 269-277 (2003).
25. Niitsu Y, Kohgo Y, Nishisato T et al. Transferrin receptors in human cancerous tissues. Tohoku J. Exp. Med. 153(3), 239-243 (1987).
26. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54(4), 561-587 (2002).
27. Tanaka T, Fujishima Y, Kaneo Y Receptor mediated endocytosis and cytotoxicity of transferrin-mitomycin C conjugate in the HepG2 cell and primary cultured rat hepatocyte. 24(3), 268-273 (2001).
28. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci. 94(10), 2135-2146 (2005).
29. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54(5), 675-693 (2002).
30. Leamon CP, Low PS. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267(35), 24966-24971 (1992).
31. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target 2(2), 101-112 (1994).
32. Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem. 271(14), 8481-8487 (1996).
33. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 56(8), 1127-1141 (2004).
34. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233(2), 134-144 (1995).
35. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277(1-2), 39-61 (2004).
36. Iinuma H, Maruyama K, Okinaga K et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99(1), 130-137 (2002).
37. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br. J. Cancer 76(1), 83-89 (1997).
38. Huwyler J, Yang J, Pardridge WM. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282(3), 1541-1546 (1997).
39. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24(11), 1977-1992 (2007).
40. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2(2), 83-90 (2002).
41. Sugahara KN, Teesalu T, Karmali PP et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6), 510-520 (2009).
42. Smith CA, De La Fuente J, Pelaz B, Furlani EP, Mullin M, Berry CC. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles. Biomaterials 31(15), 4392-4400 (2010).
43. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl Acad. Sci. USA 98(15), 8786-8791 (2001).
44. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1(3), 297-315 (2006).
45. Mattheolabakis G, Nie T, Constantinides PP, Rigas B. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Pharm. Res. 29(6), 1435-1443 (2011).
46. Nie T, Wong CC, Alston N, Aro P, Constantinides PP, Rigas B. Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: Anti-cancer activity in vitro and in vivo. Br. J. Pharmacol. 166(3), 991-1001 (2012).
47. Sun Y, Rowehl LM, Huang L et al. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: An effect controlled by the thioredoxin system. Breast Cancer Res. 14(1), R20 (2012).
48. Torchilin VP, Khaw BA, Smirnov VN, Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89(4), 1114-1119 (1979).
49. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239(2), 133-144 (1995).
50. Martin FJ, Hubbell WL, Papahadjopoulos D. Immunospecific targeting of liposomes to cells: A novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry 20(14), 4229-4238 (1981).
51. Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257(1), 286-288 (1982).
52. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237(2), 99-108 (1995).
53. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: Coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1149(1), 180-184 (1993).
54. Huang L, Connor J, Wang CY. pH-sensitive immunoliposomes. Methods Enzymol. 149, 88-99 (1987).
55. Wang CY, Huang L. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc. Natl Acad. Sci. USA 84(22), 7851-7855 (1987).
56. Connor J, Yatvin MB, Huang L. pH-sensitive liposomes: Acid-induced liposome fusion. Proc. Natl Acad. Sci. USA 81(6), 1715-1718 (1984).
57. Ahmed F, Pakunlu RI, Srinivas G et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol. Pharm. 3(3), 340-350 (2006).
58. Meng F, Zhong Z, Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 10(2), 197-209 (2009).
59. Lee JS, Feijen J. Polymersomes for drug delivery: design, formation and characterization. J. Control Release 161(2), 473-483 (2011).
60. Wang L, Tabor R, Eastoe J, Li X, Heenan RK, Dong J. Formation and stability of nanoemulsions with mixed ionic-nonionic surfactants. Phys. Chem. Chem. Phys. 11(42), 9772-9778 (2009).
61. Bilbao-Sainz C, Avena-Bustillos RJ, Wood DF, Williams TG, McHugh TH. Nanoemulsions prepared by a low-energy emulsification method applied to edible films. J. Agric. Food Chem. 58(22), 11932-11938 (2010).
62. Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev. 56(9), 1243-1255 (2004).
63. Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60(6), 757-767 (2008).
64. Constantinides PP, Lambert KJ, Tustian AK et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17(2), 175-182 (2000).
65. Bogdanova N, Lissianskaya A, Gorelov A, Moiseyenko V, Golubev A, Weiden P. TOCOSOL (TM) Paclitaxel (Paclitaxel injectable emulsion): Phase 1-2 study of weekly administration in patients with non-small cell lung, ovarian, urothelial transitional cell or colorectal carcinoma. Clin. Cancer Res. 9(16), 6136S-6137S (2003).
66. Lissianskaya A, Gershanovich M, Ognerubov N, Golubeva O, Pratt J. Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 22(14S), 5047 (2004).
67. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (Sln) for controlled drug-delivery .1. production, characterization and sterilization. J. Control. Release 30(1), 83-96 (1994).
68. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron-radiation x-ray-diffraction. Int. J. Pharmaceut. 93(1-3), 189-199 (1993).
69. Westesen K. Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality. Colloid Polym. Sci. 278(7), 608-618 (2000).
70. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56(9), 1257-1272 (2004).
71. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control Release 59(3), 299-307 (1999).
72. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 40(3), 281-286 (1999).
73. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161-177 (2000).
74. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54(Suppl. 1), S131-S155 (2002).
75. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10(4), 305-309 (2000).
76. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001).
77. Dong X, Mattingly CA, Tseng MT et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 69(9), 3918-3926 (2009).
78. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control Release 70(1-2), 1-20 (2001).
79. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54(5), 631-651 (2002).
80. Storm G, Belliot SO, Daemen T, Lasic DD Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. 17(1), 31-48 (1995).
81. Bakandritsos A, Mattheolabakis G, Zboril R et al. Preparation, stability and cytocompatibility of magnetic/PLA-PEG hybrids. Nanoscale 2(4), 564-572 (2010).
82. Gou M, Zheng X, Men K et al. Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles. Pharm. Res. 26(9), 2164-2173 (2009).
83. Gou M, Zheng L, Peng X et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)- poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int. J. Pharm. 375(1-2), 170-176 (2009).
84. Jeon SI, Lee JH, Andrade JD, Degennes PG. Protein surface interactions in the presence of polyethylene oxide .1. simplified theory. J. Colloid Interf. Sci. 142(1), 149-158 (1991).
85. Jeon SI, Andrade JD. Protein surface interactions in the presence of polyethylene oxide .2. effect of protein size. J. Colloid Interf. Sci. 142(1), 159-166 (1991).
86. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur. J. Pharm. Biopharm. 71(2), 190-195 (2009).
87. Kim SC, Kim DW, Shim YH et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control Release 72(1-3), 191-202 (2001).
88. Torchilin VP. Multifunctional pharmaceutical nanocarrires. Springer, NY, USA (2008).
89. Vassiliou AA, Papadimitriou SA, Bikiaris DN, Mattheolabakis G, Avgoustakis K. Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers. J. Control Release 148(3), 388-395 (2010).
90. Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 61(13), 1189-1192 (2009).
91. Yurkovetskiy AV, Fram RJ. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliv. Rev. 61(13), 1193-1202 (2009).
92. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev. 60(15), 1638-1649 (2008).
93. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 58(15), 1655-1670 (2006).
94. Overstreet DJ, Dutta D, Stabenfeldt SE, Vernon BL. Injectable hydrogels. J. Polym. Sci. Pol. Phys. 50(13), 881-903 (2012).
95. Tsitsilianis C. Responsive reversible hydrogels from associative 'smart' macromolecules. Soft Matter 6(11), 2372-2388 (2010).
96. Medina SH, El-Sayed MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev. 109(7), 3141-3157 (2009).
97. Caminade AM, Laurent R, Majoral JP. Characterization of dendrimers. Adv. Drug Deliv. Rev. 57(15), 2130-2146 (2005).
98. Froehling PE. Dendrimers and dyes - a review. Dyes Pigm. 48(3), 187-195 (2001).
99. Bosman AW, Janssen HM, Meijer EW. About dendrimers: Structure, physical properties, and applications. Chem. Rev. 99(7), 1665-1688 (1999).
100. Frechet JM. Functional polymers and dendrimers: Reactivity, molecular architecture, and interfacial energy. Science 263(5154), 1710-1715 (1994).
101. Agarwal A, Asthana A, Gupta U, Jain NK. Tumour and dendrimers: A review on drug delivery aspects. J. Pharm. Pharmacol. 60(6), 671-688 (2008).
102. Kannan S, Kolhe P, Raykova V et al. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J. Biomater. Sci. Polym. Ed. 15(3), 311-330 (2004).
103. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug. Chem. 16(2), 330-337 (2005).
104. Shukla S, Wu G, Chatterjee M et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug. Chem. 14(1), 158-167 (2003).
105. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim. Pol. 48(1), 199-208 (2001).
106. Chen W, Turro NJ, Tomalia DA. Using ethidium bromide to probe the interactions between DNA and dendrimers. Langmuir 16(1), 15-19 (2000).
107. Li J, Piehler LT, Qin D, Baker JR, Tomalia DA, Meier DJ. Visualization and characterization of poly(amidoamine) dendrimers by atomic force microscopy. Langmuir 16(13), 5613-5616 (2000).
108. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliv. Rev. 60(9), 1037-1055 (2008).
109. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11(6), 910-917 (2000).
110. Quintana A, Raczka E, Piehler L et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharmaceut. Res. 19(9), 1310-1316 (2002).
111. Bekyarova E, Ni Y, Malarkey EB et al. Applications of carbon nanotubes in biotechnology and biomedicine. J. Biomed. Nanotechnol. 1(1), 3-17 (2005).
112. Lin Y, Taylor S, Li HP et al. Advances toward bioapplications of carbon nanotubes. J. Mater. Chem. 14(4), 527-541 (2004).
113. Baddour C, Briens C. Carbon nanotube synthesis: A review. Int. J. Chem. React. Eng. 3(1), 1-20 (2005).
114. Richard C, Balavoine F, Schultz P, Ebbesen TW, Mioskowski C. Supramolecular self-assembly of lipid derivatives on carbon nanotubes. Science 300(5620), 775-778 (2003).
115. Wang S, Humphreys ES, Chung SY et al. Peptides with selective affinity for carbon nanotubes. Nat. Mater. 2(3), 196-200 (2003).
116. Islam MF, Rojas E, Bergey DM, Johnson AT, Yodh AG. High weight fraction surfactant solubilization of single-wall carbon nanotubes in water. Nano. Lett. 3(2), 269-273 (2003).
117. Tagmatarchis N, Prato M. Functionalization of carbon nanotubes via 1,3-dipolar cycloadditions. J. Mater. Chem. 14(4), 437-439 (2004).
118. Hirsch A. Functionalization of single-walled carbon nanotubes. Angew Chem. Int. Ed. Engl. 41(11), 1853-1859 (2002).
119. Dyke CA, Tour JM. Overcoming the insolubility of carbon nanotubes through high degrees of sidewall functionalization. Chem. Eur. J. 10(4), 813-817 (2004).
120. Pantarotto D, Briand JP, Prato M, Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem. Commun. 1, 16-17 (2004).
121. Kam NWS, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells. J. Am. Chem. Soc. 126(22), 6850-6851 (2004).
122. Pantarotto D, Singh R, Mccarthy D et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem. Int. Ed. Engl. 43(39), 5242-5246 (2004).
123. Wu W, Wieckowski S, Pastorin G et al. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem. Int. Edit. 44(39), 6358-6362 (2005).
124. Kostarelos K, Lacerda L, Pastorin G et al. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2(2), 108-113 (2007).
125. Poland CA, Duffin R, Kinloch I et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 3(7), 423-428 (2008).
126. Firme CP 3rd, Bandaru PR. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 6(2), 245-256 (2010).
127. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm. Res. 28(2), 237-259 (2011).
128. Bakandritsos A, Mattheolabakis G, Chatzikyriakos G et al. Doxorubicin nanocarriers based on magnetic colloids with a bio-polyelectrolyte corona and high non-linear optical response: Synthesis, characterization, and properties. Adv. Funct. Mater. 21(8), 1465-1475 (2011).
129. Colombo M, Carregal-Romero S, Casula MF et al. Biological applications of magnetic nanoparticles. Chem. Soc. Rev. 41, 4306-4334 (2012).
130. Kohler N, Sun C, Wang J, Zhang MQ. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21(19), 8858-8864 (2005).